
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2023

Commission File Number: 001-39461

NANO-X IMAGING LTD

Communications Center
Neve Ilan, Israel 9085000
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Management of NANO-X IMAGING LTD will host investor day on December 4, 2023. A copy of the presentation is attached hereto as Exhibit 99.1, and incorporated herein by reference.

The information in this Form 6-K, including the information set forth in Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

EXHIBIT INDEX

| Exhibit No. | Exhibit |
|-------------|-----------------------------------------------------------------|
| 99.1 | NANO-X IMAGING LTD's Investor Day Presentation. |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NANO-X IMAGING LTD

By: /s/ Ran Daniel
Name: Ran Daniel
Title: Chief Financial Officer

Date: December 4, 2023



Investor Day

December 2023

Disclaimer

Disclaimers

This presentation has been prepared by NANO-X IMAGING LTD ("Nanox" or the "Company") and includes market data and other information from sources believed by the Company to be reliable. For example, industry and market data, including Nanox's own research, and surveys or industry publications and surveys as well as public information about Nanox's customers and discussion with them. Some data are also based on Nanox's good-faith estimates, which are derived from Nanox's review of internal sources as well as the other sources described above. Although Nanox believes these sources are reliable, Nanox has not independently verified the information is accurate and complete. As a result, you should be aware that market share, ranking and other similar data set forth in this presentation, and estimates and beliefs based on such data may not be reliable.

Market and Industry Data and Customer Information

Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by Nanox or any director, employee, agent, or adviser of the Company. This presentation does not purport to be all inclusive or to contain all of the information about the Company. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy the Company's securities, nor shall there be any sale of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any estimates contained in this presentation as to events that may occur in the future (including forward looking statements) are based upon assumptions believed by the Company to be reasonable at the time made.

Forward-Looking Information Statement

Statements contained in this presentation concerning expectations, beliefs, plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact are "forward-looking statements." These statements often include words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "target," "project," "forecast," "seek," "will," "may," "should," "could," "would" or similar expressions. Although Nanox believes that the expectations and assumptions reflected in these statements are reasonable, these expectations or forecasts of future performance may not prove to be correct. Forward-looking statements are subject to many risks and uncertainties, and actual results may differ materially from the results discussed in forward-looking statements. The following are among the important factors that could cause actual results to differ materially from the forward-looking statements: risks related to (i) Nanox's ability to continue to develop of the Nanox imaging system; (ii) Nanox's ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox's expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements;

(iv) Nanox's ability to realize the anticipated benefits of acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (v) Nanox's ability to enter and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vi) the market acceptance of the Nanox imaging system and the proposed business model; (vii) Nanox's expectations regarding collaborations with third-parties and their potential benefits; and (viii) Nanox's ability to conduct business globally; (ix) changes in global, political, economic, business, competitive, market and regulatory forces; (x) risks related to the war in Israel; and (xi) risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises, among other things.

Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Other risks and uncertainties of which Nanox is not currently aware may also affect these forward-looking statements. The reader should not place undue reliance on any forward-looking statements included in this presentation. These statements speak only as of the date made and Nanox is under no obligation and disavows any obligation to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation.

These risks and uncertainties are described more fully under the caption "Risk Factors" in the Company's filings with the Securities and Exchange Commission.

On the agenda

Erez Meltzer

 Chief Executive Officer
and Board Member

Opening remarks

Erez Meltzer

 Chief Executive Officer
and Board Member

U.S. go - to - market

Ofir Koren

 General Manager,
ARC division

 Global Commercialization
Regulatory pathway

Dr. Orit Wimpfheimer

Chief Medical Officer

 Clinical benefits of the Nanox.ARC
Nanox.AI

Erez Meltzer

 Chief Executive Officer
and Board Member

Innovation

Jim Dara

 General Manager
Source & Services &
Head of Nanox USA

 Source and services
OEM

Ran Daniel

Chief Financial Officer

Financial Highlights

Erez Meltzer

 Chief Executive Officer
and Board Member

Closing Remarks

Q&A Session

Erez Meltzer Chief Executive Officer

Opening Remarks



NANOX

The Nanox Impact



The N Culture

Resilience

Agility & Flexibility

Winning Spirit

Dedication

Passion

Creativity



Values

Innovation in medical technology, and AI is crucial for achieving global health equity



Erez Meltzer

Chief Executive Officer

U.S. Go-to-Market



Nanox.ARC



FDA
CLEARED

CE
PENDING

FDA Clearance April 2023

FIRST U.S. DEMO CENTER

NANOX U.S. Go-to-Market Nanox Investor Day 10

FIRST U.S. DEMO CENTER

TOGETHER FOR BETTER HEALTH

Nanox.ARC Ecosystem

00:17.28

U.S. Deployment and Strategy



Demonstration center for the Nanox.ARC, which will provide potential buyers with a live demonstration of the technology, and a clinical site that can raise awareness of the Nanox.ARC among key opinion leaders, radiologists, and hospital system personnel



Commercial use

U.S. Go-to-Market strategy

Our U.S. go to market strategy is comprised of three primary components:



Customer Targeting



Building a Sales Team



Using a Hybrid Business Model

Customer Targeting

01 Type of medical facility



Imaging Center



Orthopedic Clinic




Urgent Care



Skilled Nursing Facilities

Customer Targeting

02 Current imaging capabilities



7 -15 studies per day

Customer Targeting

03 Geographic location, namely rural vs. urban

Leveraging CT & SNF / FSED / UC density and Medicare enrollment, the Atlantic region may offer strong opportunity for TS; cluster targeting may support efficient Nanox commercial resource utilization.



Nanox. ARC U.S. Professional Network



Holistic Customer Support



Nanox.ARC Call Center (Global)



Installation

- Site Readiness
- Equipment Transport
- Installation & Calibration
- Customer ATP



- 626 Activity Alignment
- Escalation Specialist
- Reporting & Follow-up



On-site Training

- Technical
- Integration support
- 626 Image Academy Training & Demonstration Bay



Nanox.ARC Status Tracking; logging, scans, errors, maintenance indications



Customer Support & Maintenance

- 24-7 Customer Support
- Spare Parts Management
- Preemptive, Preventative
- CRM reporting

Potential Future Sales & Distribution Partner

626 Image Academy



U.S. Business Model



MSAAS

Per scan
\$30

Scans
7 -15 per day



CAPEX and Hybrid, with financing

Per System



Ofir Koren General Manager, ARC Division

Global Commercialization
Regulatory Pathway




NANOX

Deployment



GCCS – Nanox’s Global Control Center System



For demonstration purposes only

Live demo on whole body phantom



Regulatory Pathway

2023

2024

| | | |
|----------------------------|-------------------------|-----------------------------------------------------|
| Current Clearance/approval | U.S. Israel Ghana | FDA 510(k) MSK AMAR MSK GFDA Whole Body |
| Submitted | EU | CE Whole Body |
| Future submission | | U.S. FDA 510(k) Chest |



Dr. Orit Wimpfheimer Chief Medical Officer

- Clinical Benefits
- Nanox.AI



Tomosynthesis – Place in Medical Imaging

Multiple Modality Thoracic Imaging and Product Comparison



X-ray

Overlapping body structures (2D)
Relatively low dose

Images: 1-2
Reading time: 110±30 sec
Dose: 0.04-0.1 mSv



Tomosynthesis

Partially **overlapping anatomy**
Relatively **low dose**

Images: 30-60
Reading time: 220±40 sec
Dose: 0.1-0.2 mSv



CT

Body structures separated
Relatively high dose

Images: Hundreds
Reading time: 600±150 sec
Dose: CT >2mSv LDCT 1-1.5 mSv

Reference doses and time figures from (Quaia et al., 2012), (Mirzai et al., 2020), (Gomi et al., 2012)

Tomosynthesis Clinical Benefits

The MSK applications of tomosynthesis compared to X-ray:

- **Improved visualization** of occult bone fractures
- **Delineate complex anatomic structures**
- **Decreased interference from cast**
- **Decreased effect of metal artifacts** (Compared with CT)
- **Visualize degenerative and inflammatory arthritis**

Right Hand



(Healthy volunteer)



Image was taken under Helsinki permit to conduct a clinical study in Israel, using our multisource Nanox.ARC system, 2023. Image courtesy of Shamir Medical Center

Left wrist with cast



(Healthy volunteer)



Image was taken under Helsinki permit to conduct a clinical study in Israel, using our multisource Nanox.ARC system, 2023. Image courtesy of Shamir Medical Center

Pelvis with sclerotic lesion



(Healthy volunteer)




Image was taken under Helsinki permit to conduct a clinical study in Israel, using our multisource Nanox.ARC system, 2023. Image courtesy of Shamir Medical Center



Ankle fracture with cast



Pelvis with fracture and metastases



Thoracic spine and rib cage



(Healthy volunteer)



Image was taken under Helsinki permit to conduct a clinical study in Israel, using our multisource Nanox.ARC system, 2023. Image courtesy of Shamir Medical Center

Tomosynthesis Clinical Benefits

Enhanced visualization to inform clinical decisions

Reduced super-imposition of normal structures may reduce false positives and help with problem solving

- Improved visualization of subtle findings
- Improved detail and sensitivity enables characterization of findings (size, borders, etc.)

Additional depth views for added information and faster diagnosis

Expedited diagnosis means faster treatment

Covered Procedure



CPT® Code 76100

Payment range \$88-\$109 (CMS)

Higher reimbursement on top of radiography



Flexible Business Model

We intend to use a hybrid approach combining a usage based MSaaS model with and a CapEx model to help promote adoption, based on different segments

Value Proposition for Nanox.ARC

Nanox.ARC is an FDA-cleared digital multi-source 3D tomosynthesis imaging system, providing advanced radiographic visualization to enhance your practice. Nanox.ARC unlocks significant value for medical practices, providers, and their patients.



Affordable, advanced digital imaging solution with a **flexible business model** including pay-per-use and no upfront capital purchase



Tomosynthesis enhances anatomy visualization and reduces the super-imposition of structures



Retain patients within your facility with more comprehensive and faster clinical care

Value Proposition for Nanox.ARC

Nanox.ARC is an FDA-cleared digital multi-source 3D tomosynthesis imaging system, providing advanced radiographic visualization to enhance your practice. Nanox.ARC unlocks significant value for medical practices, providers, and their patients.



Leverage existing payer coverage with higher reimbursement on top of radiology: CPT Code 76100



Opportunity to expand revenue stream at your facility via an immediate new revenue source



Future-ready: Nanox.ARC and Nanox.CLOUD are flexible, modular, scalable, and ready to easily add future capabilities; future regulatory clearances unlock new clinical indications for use in your practice

Nanox.AI





“

We have implemented NanoxAI HealthCCS solution in our HMO owned (Clalit) teaching hospital and **have seen great value in identifying new patients with high calcium on chest CT scans.** Even in a preventive oriented population as the one we have in our organization **we were impressed with the number of unknown patients suffering from CVD.”**



Prof. Ashraf Hamdan, MD

Head of cardiovascular imaging,
Rabin medical center

Assessment of Coronary Artery Calcification on Non-Gated Conventional CT Scans Using Artificial Intelligence Integration

Amos J, Rabinov M, Tamir S, Horowitz G, Hadad N, Sheynokh A, Avri Y, Wisniam M, Khelife M, Dargatzis G, Rabinov A, Shafiq G, Kimmel Y, Nactemias K, Mizrahi N, Kuznowski R, Hamdan A
 1 Rabin Medical Center, Department of Cardiology | 2 Rabin Medical Center, Department of Radiology, Petach Tikva | Tel Aviv University, Israel | 3 Nanox AI, Shifayim, Israel

Background

- Coronary Artery Calcification (CAC) is a widely used method for evaluating the extent of coronary artery disease.
- Recent advancements in Artificial Intelligence (AI) technology have led to the development of an automatic CAC scoring software applied on standard chest CT scans.
- The objective of this study was to assess the impact of AI-based CAC.

Methods


- We used the Nanox AI HealthCCS (FDA cleared) software to estimate CACs from non-gated, non-contrast chest CT scans. Qualitative assessment was performed by two radiologists who reviewed each case and indicated any over/underestimation provided by the software.
- Patients were categorized by CAC into three groups: Low calcium score (CAC < 100), Moderate calcium score (CAC 100-300), and Severe calcium score (CAC > 300). Patients with prior myocardial infarction, coronary intervention, coronary artery bypass graft, and renal artifacts were excluded.

Results

- 438 consecutive patients undergoing chest CT between January and July 2023 were enrolled in the study. 328 patients were included (75% without access to medical history and 25% who had access), while 110 out of 328 patients (33%) had a Severe CAC score, 88 patients (27%) had a Moderate CAC score, and 137 patients (42%) had a Low CAC score (Figure).
- Patients with High CAC scores were referred to specialized preventive cardiology clinics for further evaluation and treatment, while patients with Low and Moderate CAC scores were referred to Primary Care Physicians for further evaluation and optimization of medical therapy.

Conclusions

- This ongoing study indicates that CAC quantification using the Nanox AI HealthCCS software on routinely performed chest CT scans can identify patients who may benefit from preventive cardiology services.
- Through the use of the Nanox AI software we were able to identify 101 (31%) new patients with Severe Coronary Artery Calcium who were previously unknown to the health system and were scheduled to visit the preventive cardiology clinic.



Of the 326 patients that were validated by radiology with available cardiac history,

27% newly identified patients with moderate coronary artery calcium were directed to PCP

31% newly identified patients with severe coronary artery calcium were directed to the outpatient preventive cardiology unit

Population Health Empower Medical Imaging



An AI system that diagnoses heart conditions before they occur:

00:04.31

The video player displays a woman in a white lab coat standing in front of a medical imaging screen. The screen shows a cross-sectional scan of a heart. The video player interface includes a play button, a progress bar, and a volume icon. The time displayed is 00:04.31.





Nanox.AI and Spectrum Health

Putting preventive healthcare into practice
January – September 2023; **2,441** new CVD patients



“We have successfully integrated the NanoxAI HealthCCS solution into our IDN, and we’ve recognized its **significant value in identifying new patients** with medium and high calcium levels on chest CT scans”



Dr. Langholz, M.D., FACC FASE
Frederick Meijer Heart and Vascular Institute Spectrum Health, Grand Rapids, MI Clinical Professor, MSU School of Medicine

*8 months, including ramp up

Erez Meltzer

Chief Executive Officer

Innovation




Nanox.CONNECT



NANOX
CONNECT

Clinical Care Workflow and Connectivity



Real-Life Circumstances in Morocco




Connect System – Bridging the Gap




NANOX
CONNECT

Studies Summary

| Distributor | Total Acquired | Uploaded |
|--------------|----------------|------------|
| [Redacted] | 1501 | 437 |
| [Redacted] | 851 | 310 |
| [Redacted] | 851 | 310 |
| [Redacted] | 650 | 127 |
| [Redacted] | 650 | 127 |
| [Redacted] | 27 | 24 |
| [Redacted] | 27 | 24 |
| Total | 1528 | 461 |



| Machine | Before Acquisition | | After Acquisition | | | | | Misc | | |
|---------|--------------------|----------|-------------------|-------------|-------------------|------------------|---------------|----------|---------|-----------|
| | Scheduled | Reserved | Acquired | Unscheduled | Emergency Studies | Emergency Images | Sent to Cloud | Uploaded | Deleted | Has Error |
| NC2 | 22 | | 27 | 3 | 1 | 3 | 26 | 24 | | 6 |
| NC6 | 587 | | 650 | 14 | 49 | 95 | 649 | 127 | | 32 |
| NC7 | 844 | | 851 | 7 | | | 851 | 310 | | 84 |



Jim Dara

GM Source & Services & Head of Nanox USA


- Source & Services
- OEM



Source and Services

Source: Nanox Emitter

- Identify and launch additional sources for Nanox chips and enabled tubes
- Generate awareness and demand for Nanox technologies across multiple industries
- Develop next generation solutions based upon our novel technologies



Services: Teleradiology


- Provide around the clock access to U.S. Board Certified radiologists
- Utilize FDA approved AI algorithms to improve productivity and reading accuracy
- Educate the benefits of Nanox.ARC DTS and support Nanox.ARC deployments with DTS trained radiologists
- Leverage existing customers and partners to successfully expand Nanox.ARC deployments



Nanox.Source Benefits

Partner feedback:

- High current density $> 1 \text{ A per cm}^2$
- Stable emission
- Flexible emitter activation
- Focal Spot flexibility
- Low gate voltage compared to CNT
- Ultra-fast X-ray switching: $< 1\mu\text{s}$
- Smaller footprint







New Business Development Tool

Not all entities have the internal expertise and equipment to assess Nanox technologies at the chip level

- Nanox DEMO Includes the necessary hardware, software and certifications to activate our chip & tube
- Allows for seamless pc connection and variable Kv, mA, ms recipe activation and pulse sequencing
- Scheduled to begin delivery to select partners in Q1 2024
- Queue of medical, industrial inspection and security companies scheduled for delivery throughout 2024



Varex Strategic Relationship



Tube Development & Production



- Varex HQ October Kickoff
- Tube Development & Prototyping
- Regulatory
- Production



Nanox.ARC System Integration



- Nanox.ARC Delivery
- Testing Protocol
- Production Testing Protocol



New Application Development



- Future Nanox.ARC
- Novel Applications
- Modified Emitter Planning



Additional Partnerships

After completing their own assessments of Nanox.SOURCE emitters:



Industrial

Having completed tube prototype development utilizing our emitter, we expect execution of a formal tube supply agreement with an industrial & medical imaging equipment manufacturer in the near future



Security

After acquiring and testing our emitters, a U.S. government agency is advancing with the acquisition of Nanox tubes for further testing and exploration towards collaboration on a new application.



Medical

After completing a formal technical assessment project around our emitters, a leading global medical technology company has purchased Nanox.SOURCE emitters for application development purposes.

Ran Daniel Chief Financial Officer

Financial Highlights



NANOX

Q3/23 Financial Highlights

\$95.6 M
Cash and CE as of
9/30/23

164
Worldwide Full Time
Employees

\$45.1M
PP&E

\$2.5M
(Q3/23)
Revenue

67.3M
Fully Diluted Shares
Outstanding

Erez Meltzer Chief Executive Officer

Closing Remarks



2024 Focus



Commercial acceleration



Business integration



U.S ramp - up



Regulation progress

Leading the Nanox I M P A C T

From Predictive to Preventive



Q&A Session



NANOX

Thank You!

